Cureteq combines asset management, biotechnology and artificial intelligence in a unique platform to drive assets efficiently and effectively to the next value inflection and beyond.
What we do
Cureteq is an asset management and biotechnology company developing innovative medicines based on a sophisticated AI platform.
Cureteq leverages AI to identify the optimal applications of a given molecule and to de-risk clinical development.
Acquired molecules are developed by individual portfolio companies to ensure the speed and agility that characterises biotech companies while retaining some of the benefits of larger organisations such as a broader access to expertise and resources, thereby getting the best of two worlds.
Portfolio companies range from very lean entities that are operating with a high degree of central support from Cureteq, to independent biotech companies with their own teams and governance, fully compatible with the venture capital investment model.
Overall, the model provides for a fast and de-risked development of new medicines to address unmet medical needs for which, they will be most effective and where they have the highest probability of becoming available to patients.
Pioneering innovation in drug development
Cureteq is pioneering a new approach to innovation in drug development through a unique platform that aims to establish a portfolio of associated yet decentralised biotech companies, or ‘teqs’. Cureteq licenses assets from biopharma and integrates a powerful and well-proven AI engine for decision making, ultimately enabling optimised, de-risked and accelerated clinical development.

Cureteq est.
Nov 2021
Privately held
10+ Employees
Strategic partners
Innoplexus
Office in Zug
Portfolio company
Oncoteq est. Apr 2022